H1 2024 Drug Landscape Review
Explore the evolving drug landscape with 566 new drugs added in the first half of 2024, focusing on key targets like CD19 and innovations in small molecule and cell therapies. Part 1 provides detailed insights into first-time approvals and discontinuations shaping the Immune Tolerance market.
Trials and Regulatory Announcements
Part 2 covers critical updates in the trial landscape, including 744 new trials and significant regulatory activity. Learn about first-time approvals, trial discontinuations, and other key regulatory developments in the Immune Tolerance space during H1 2024.
Deals and Company Insights
Uncover the top deals and company movements driving the Immune Tolerance market in Part 3. From the biggest deals of H1 2024 to future market trends, this final installment offers exclusive insights and analysis to guide your strategic decisions.
About the H1 2024 Landscape Review
With traditional oncology drugs now being repurposed for autoimmune diseases and cutting-edge therapies like cell therapies, bispecific antibodies, and gene therapies taking center stage, navigating this complex landscape has never been more critical. Beacon’s Immune Tolerance Database offers unrivalled depth in tracking all therapeutic classes and technologies being developed in this space, providing you with the comprehensive insights needed to make informed decisions.
Sign up now to download the full H1 2024 Immune Tolerance Landscape Review Series and gain exclusive insights into the ever-changing Immune Tolerance market.
You May Also Be Interested In...
H1 2024 Immune Tolerance Landscape Review
H1 2024 Bispecific Landscape Review
H1 2024 RNA Landscape Review
H1 2024 Gene Therapy Landscape Review
H1 2024 Checkpoint Landscape Review
H1 2024 ADC Landscape Review
Find Out More
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
